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The purpose of this paper is to review the surgical options available for the management of pediatric glaucoma, to evaluate their
advantages and disadvantages together with their long-term efficacy, all with the intent to give guidelines to physicians on which
elements are to be considered when taking a surgical decision. Currently there is a range of surgical procedures that are being used
for the management of pediatric glaucoma. Within these, some are completely new approaches, while others are improvements
of the more traditional procedures. Throughout this vast range of surgical options, angle surgery remains the first choice in mild
cases and both goniotomy and trabeculotomy have good success rates. Trabeculectomy with or without mitomycin C (MMC) is
preferred in refractory cases, in aphakic eyes, and in older children. GDIs have a good success rate in aphakic eyes. Nonpenetrating
deep sclerectomy is still rarely used; nevertheless the results of ongoing studies are encouraging. The different clinical situations
should always be weighed against the risks associated with the procedures for the individual patients. Glaucomatous progression
can occur many years after its stabilization and at any time during the follow-up period; for this reason life-long assessment is
necessary.
1. Introduction
Pediatric glaucoma is a condition characterized by an ele-
vated intraocular pressure (IOP) and optic nerve damage and
it can be potential cause of blindness [1].
The most common classification is the following.
(1) Primary congenital glaucoma, including isolated idi-
opathic developmental anomalies of the angle struc-
tures.
(2) Glaucoma arises in a series of systemic diseases
some associated with iridocorneal trabeculodysgen-
esis syndrome such as Axenfeld Rieger syndrome or
Peter’s anomaly [2], the phakomatoses in particular
Sturge-Weber syndrome and its variants [3–5]. It can
be associated also with neurofibroamatosis [6, 7],
homocystinuria, Lowe’s syndrome, mucopolysaccha-
ridosis, juvenile xanthogranuloma [8, 9].
(3) Secondary glaucoma associated with acquired ocular
disease.
Depending on the timing of the diagnosis and on features
and circumstances of presentation of the glaucoma, aspects
that must all be very carefully evaluated, surgery represents
the mainstay of treatment, while topical medication may be
needed for additional IOP control following surgery or as a
temporary measure.
Currently, there are different surgical options, includ-
ing newer surgical procedures that are improvements of
the traditional ones; these in association with the use of
antimetabolites and of new viewer systems contribute greatly
to the improvement of the prognosis of this disease.
The purpose of this paper is to analyze the surgical
options available for the management of pediatric glaucoma
and to evaluate their advantages and disadvantages together
with their long-term efficacy, all with the intent to give guide-
lines to physicians on which elements are to be considered
when taking a surgical decision.
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Table 1: Summary of angle surgery results in patients with primary congenital glaucoma.
Years Author Surgical technique Eyes Follow-up (years) End point Success rate
1953 Barkan Goniotomy 196 17 yrs IOP <20mmHg 80%
1982 Shaffer Goniotomy 287 15 yrs IOP <20mmHg 76.7%
1979 Lunz Trabeculotomy 86 6.5 yrs IOP <18mmHg 89.5%
2007 Yalvac Trabeculotomy 24 3 yrs IOP <18mmHg
92% 1 yr
82% 2 yrs
74% 3 yrs
Table 2: Summary of trabeculectomy surgery in primary congenital glaucoma.
Years Author Surgical technique Eyes Follow-up End point Success rate%
2004 Rodrigues
Trabeculectomy:
30 eyes with MMC∗
61 eyes without MMC
91
Patients with MMC
70.2 ± 58.2 months
Patients without MMC
43.8 ± 31.3 months
IOP between 15 and
21mmHg ∗∗
2010 Madhy
Trabeculectomy:
15 eyes MMC and
amniotic membrane
transplantation
15 eyes
trabeculectomy
MMC∗
30 18 months IOP between 15 and21mmHg
80
60
Intraocular pressure (IOP), mitomycin C (MMC), and millimeters of mercury (mmHg).
∗MMC 0.4mg/mL for 3 minutes.
∗∗The authors did not report values of success rate; they reported 𝑃 values obtained by Fisher exact test for categorical variables and survival analysis to access
the success rate through time. No significant difference on the failure time of the procedure, for both success IOP values considered, was observed between the
groups (P = 0.746 for IOP <21mmHg and P = 0.216 for IOP ≤15mmHg).
2. Angle Surgery: Goniotomy and
Trabeculotomy
2.1. Goniotomy. The initial approach for primary congenital
glaucoma is still angle surgery: goniotomy in the case of a
clear cornea or trabeculotomy in the case of a cloudier cornea
(Tables 1 and 2). Experienced surgeons have a high rate of
success with this technique. Nonetheless, the patient should
fit within certain criteria such as the primary congenital
glaucoma with no other ocular or systemic anomalies, first
diagnosed at least one month after birth but before on year of
age, and the corneal diameters need to be less than 14mm.
Goniotomy was described for the first time by Barkan in
1948 [10] although his pioneer was actually de Vincentis who
first performed it in 1893 [11]. The main aims and steps of
this procedure have remained the same throughout the years;
however, some modifications have been introduced, such as
the use of a surgical microscope, the introduction of new
goniolens (Koeppe, Barkan, Ritch), and the use of viscoelastic
material to protect the cornea and lens.
The surgical steps include entering the anterior chamber,
using a goniotomy knife to perform a corneal incision so as
to reach the opposite side of the chamber and then incise the
trabecular meshwork for 100–110 degrees, visualized using
a goniolens. One of the most recently introduced is the Ritch
lens; this is a direct lens that allows a 160 degree view of the
angle and obstructs only half of the cornea thus making it
easier to introduce the goniotomy instrument into the eye
while the goniolens is in place. In case of failure it can be
repeated.
Barkan in 1953 described the result of his 17 years of work
with goniotomy in congenital glaucoma; he reported an 80%
success rate in 188 eyes, with postoperative IOP values less
than 20mmHg without medications [12].
In 1982 Shaffer described results in 287 operated eyes.
Glaucoma was considered cured if the intraocular pressure
remained below 20mmHgwithout medication for at least six
months and cupping of the optic nerve was either the same
or improved. The success rate was 76.7%. However, when the
signs or symptoms of glaucoma were present at the birth or
above the age of 24 months, the success rate was close to
30%. In contrast the success rate improved to 94% in cases
diagnosed between the age of 1 and 24 months after one or
two goniotomies [13]. This difference can be explained by the
microstructural changes that are detectable in the different
age groups; indeed patients over the age of 24 months are
known to have less cellularity and more collagenous tissue
with respect to younger patients. In the same work he also
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Table 3: Summary of trabeculectomy surgery in primary congenital glaucoma and secondary glaucoma including: aphakia, aniridia, juvenile
open angle glaucoma, uveitis, and Sturge-Weber syndrome.
Years Author Surgical technique Eyes Follow-up End point Success rate%
1999 Freedman
Mmc trabeculectomy
postoperative 5 FU or
suture lysis
21 23 months 4< IOP >16mmHg 52.4
2000 Snir
Trabeculectomy
5 FU or MMC plus
postoperative 5 FU
12 25.8 ± 12.2 months IOP <20mmHg 58.3
2008 Giampani MMC∗ trabeculectomy 114 61.2 ± 26.1 months 5< IOP <21mmHg 55.26
Intraocular pressure (IOP), millimeters of mercury (mmHg), years (yrs), mitomycin C (MMC), and 5 fluorouracile (5-FU).
∗MMC 0.4mg/mL for 3 minutes.
described that after 15 years of follow-up 3 patients had an
increase between 20 and 30 in IOP and therefore required
medical therapy [13].
Another study discussed long-term goniotomy compli-
cations; in particular the authors described a risk of relapse
of glaucoma for at least 15 years. Patients whose symptoms
of congenital glaucoma presented at birth were more likely
to relapse than those whose symptoms developed in the first
few months of life. Furthermore, eyes that required multiple
goniotomies in infancy weremore likely to relapse than those
controlled by a single procedure (Table 3) [14].
Complications include mild and transient hyphema,
cyclodialysis, iridodialysis, peripheral anterior synechiae, and
cataract formation.
The preoperative presence of angular synechiae of more
than 180∘ of circumference is associated with a failure rate of
100%. Some authors proposed preoperative laser treatment of
synechiae with YAG laser [15].
2.2. Trabeculotomy. Trabeculotomy was described for the
first time in 1960 by Burian; this surgical technique provided
the identification of Schlemm’s canal, its radial incision, and
incannulation for 360 degrees with a nylon filament. Burian
described an elevated success rate [16]; however, potential
false passages and the difficulty to control the nylon filament
made the modification of the surgical technique necessary.
In 1970 Harms and Dannheim created a scleral superior
flap, similar to the flap created for trabeculectomy, so as
to have a better identification of Schlemm’s canal. He also
introduced a new instrument:Harms’ trabeculotome that acts
for approximately 120∘ and has two parallel arms that help
the surgeon by providing an external guide. If one procedure
alone is not enough, it can be repeated [17].
Also Allen and Burian described trabeculotomy using a
rigid probe with satisfactory results [18].
Nowell-designed studies to compare the efficacy of a rigid
probe versus the nylon filaments have been conducted as of
yet, but the small studies available in literature show a similar
efficacy between the two instruments.
In 1979 Luntz reported the surgical results of standard
trabeculotomy for the treatment of congenital glaucoma in
86 eyes; he described a success rate of 89.5% (IOP 18mmHg
or less under anesthesia using Schiotz tonometer).The age of
the patients ranged from 2 weeks to 12 years and the mean
follow-up was approximately 6.5 years [19].
Yalvac et al. reported his surgical results with standard
trabeculotomy after 1, 2, and 3 years of follow-up in 24
patients the success rate was, respectively, 92%, 82%, and 74%.
The end point was IOP less than 18mmHg and more than
5mmHg with a single intervention, stabilization of cup disc
ratio, and lack of corneal enlargement [20].
A recent study by Ou and Caprioli reported a success
rate ranging from 87% to 92% in case of primary congenital
glaucoma presenting before one year of age [21].
In the last years a 360∘ trabeculotomywith an illuminated
microcatheter has been described.
The use of illuminated probes allows for controlled
visualization of the position of the catheter while advancing
along Shlemm’s canal. Dao et al. reported a 75% success rate in
achieving 360∘ cannulation as an initial procedure in children
with primary congenital glaucoma [22].
Several studies compared the efficacy of goniotomy and
trabeculotomy and concluded that both are successful tech-
niques [23, 24].There is a general consensus to use goniotomy
for initial formswith clear cornea and trabeculotomy formild
severe forms with corneal opacity.
Complications include transient hyphema, choroidal
detachments or hemorrhage, and false passage into the eye;
less common complications are iridodialysis and rupture of
the Descemet membrane [25, 26].
2.3. Trabeculectomy. Trabeculectomy is a filtering procedure
that is generally utilized if angle surgery in primary congeni-
tal glaucoma fails to work; however, some surgeons prefer to
perform it as primary choice in aphakic glaucoma [25].
Although several studies report acceptable results, the
success rate is lower than that reported in adult patients
and varies from 35 to 50% [26–30]. Several studies report
the enhanced success (54% to 85%) of this procedure when
used as the primary intervention for congenital glaucoma
[31]. Trabeculectomy presents special technical difficulties in
childhood because buphthalmic eyes are bigger than usual
and the lumbar anatomy is frequently impaired and it can lead
to iris and ciliary body incarceration and vitreous loss [30–
33]. Furthermore in childhood there is an exuberant fibrotic
postoperative response with scar formation which occludes
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the filtering site and causes long-term trabeculectomy failure.
To obviate this drawback the use of antimetabolites has
been introduced. Freedman et al. retrospectively reviewed 21
eyes of 17 patients (mean age 2.6 years, minimum 1 month
maximum 16 years) who underwent mitomycin C (MMC)
trabeculectomy, selective use of postoperative 5 fluorouracile
(5-FU), and diode laser suture lyses in patients suffering from
refractory primary and secondary glaucoma. The follow-up
period for all cases was 16.4 ± 11.4months. The preoperative
IOP of 34.1 ± 5.7mmHg was reduced to the mean values
of 16.9 ± 11.2mmHg at last follow-up, with a mean IOP
decrement of 17.2 ± 9.1mmHg (𝑃 ≤ 0.001). The use of
preoperative eye drops (for all cases) was reduced from 2.4 ±
0.6 before operation to 1.1 ± 1.0 after operation (𝑃 ≤ 0.001).
The cumulative success rate was 54.2%. A lower success
rate was noted in patients younger than 1 year of age (30%)
compared with those older than one year (73%) and in
aphakic eyes (2%) comparedwith the phakic ones (64%) [34].
The reason is unknown. Beauchamp and Parks described
a more exuberant healing response which together with a
thicker Tenon’s layer and lower scleral rigidity and thickness
may be considered responsible [30]. Although others have
noted poor success of MMC-augmented trabeculectomy in
aphakic children, the reasons for frequent failure in these
patients are unknown [35]. Susanna Jr. et al. reported an
overall success rate (IOP between 4 and 21mmHg) in 67% of
79 eyes patients (mean age of 76 months and a mean follow-
up of 17 months), with devastating complications in 3 eyes
[36].
The use of antimetabolites led to the improvement of the
prognosis, but at the same time other complications were
reported: thin avascular bleb, bleb related endophthalmitis,
and long-term hypotonia and bleb leak carry substantial
ocularmorbidity and the potential for visual loss as well as the
need for additional surgery. An increased incidence of post-
operative complications is reported inmitomycin trabeculec-
tomy comparing to trabeculectomy without antimetabolites
[37–39]. Sidoti et al. reported a significant incidence of
endophthalmitis in childhood compared to the rates reported
in adults [28].
In the early postoperative period, themost common com-
plications faced by the glaucoma surgeons involve either ele-
vated IOP or hypotonia. Other complications are wound leak,
choroidal hemorrhage, malignant glaucoma, cystoidmacular
edema, encapsulated bleb iris prolapsed, and synechiae [28–
40].
Major intraoperative complications in particular expul-
sive choroidal hemorrhage and intraoperative choroidal effu-
sion are more frequent in eyes with glaucoma secondary to
Sturge-Weber syndrome.
The reason is due to vascular anomalies and increased
pressure in episcleral veins, ciliary body veins, and choroidal
veins that quickly loose fluid from the intravascular to the
extravascular space when eyes are opened and intraocular
pressure suddenly declines. To prevent this rare but potential
catastrophic event the authors have proposed prophylac-
tic intervention such as posterior sclerotomy, prophylactic
radiotherapy or laser photocoagulation of the choroidal
hemangioma, or electrocautery of the anterior episcleral vas-
cular anomaly, also the reduction of intraoperative hypotonia
by a rapid closure of the scleral flap seem to be effective
to reduce the risk of expulsive choroidal hemorrhage and
intraoperative choroidal effusion [41].
2.4. GlaucomaDrainage Implants. Glaucoma drainage implants
(GDIs) provide an alternative option for IOP reduction in
complicated pediatric glaucomas that are refractory to angle
or filtering surgery. GDIs employ a silicon tube placed in the
anterior chamber to shunt aqueous humor to the subconjunc-
tival space where it is connected to a plate positioned in the
equator region. A fibrous capsule forms around this plate.The
size and the material of the plates vary between the different
devices.
The first drainage system utilized was the Molteno valves
in 1970 [42]. Afterwards other valves were introduced; the
most utilized actually together with Molteno implants are
Bearveldt and Ahmed valves [43].
The Ahmed valve is a device with a unidirectional valve
restriction flow mechanism, designed to open when IOP is
higher than 8mmHg.This design is highly effective to reduce
postoperative hypotonia compared to nonvalved devices
which requires a two-step procedure to prevent postsurgical
hypotonia and the use of medication to control IOP until
the tube opens. Success rate in the different studies varies
considerably from 31.3% to 92.7%; this huge difference is
due to the different populations enrolled, different devices
utilized, and different follow-up lengths (Tables 4 and 5)
[4–47]. For instance Al-Mobarak and Khan reported a low
success rate of 31% after two years in patients younger than
2 years while Al-Mobarak and Khan reported a success
rate of 86% in patients with a median age of 6 years [48].
Yang and Park reported in 38 eyes with congenital glaucoma
and 41 with aphakic glaucoma success rates of 92 and 90%,
respectively, at 1 year of follow-up which decreased to 42 and
55% after 10 years [49]. Several studies performed on young
patients did not show significant differences in postoperative
IOP values [50, 51].
A meta-analysis of aqueous shunts by Minckler et al.
revealed no advantages to the adjunctive use of antifi-
brotic agents or systemic corticosteroids [52]. The paucity
of evidence that MMC improves outcomes and its potential
complications have led to their more limited use [53, 54].
Freedman et al. comparison of GDIs and MMC tra-
beculectomy shows a major success rate of the former one
in both short and long term (87% versus 36% at one year
and 53% versus 19% at 6 six years) [55]. These results are
confirmed in other studies. Pakravan et al. reported a success
rate of 87% (IOP between 5 and 21mmHg) in aphakic
glaucoma treated with Ahmed implants versus 67% in those
treated with MMC trabeculectomy 40%. He also reported an
increase of complication rate in the MMC trabeculectomy
group (40% versus 26.7%) [56].
The complications associated with GDIs are largely
reported and seem to be more frequent in childhood
compared to adulthood. The most frequent complications
are shallows and flats in the anterior chamber, hypotonia,
hyphema, choroidal effusion, corneal tube contact, iris abnor-
malities, and endophthalmitis associatedwith tube extrusion.
Strabismus has been described after GDIs and it is due to the
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Table 4: Summary of GDIs implants surgery in patients with primary congenital glaucoma.
Years Author Type of valve implanted Eyes Follow-up End point Success rate%
2004 Al Torbak Ahmed with corneal transplant 20 30.9 months
IOP between 5 and
21mmHg without
medical or surgery
additional
intervention
44 at 2 yrs
33 at 4 yrs
2014 Audrey Bearveldt 45 30 months IOP <21mmHg
93.3 at 3–9 months
86.7 at 12–18
months 86.7 at
24–30 months
2014 Reza Razeghinejad Ahmed 33 32 ± 18.3 months IOP <21mmHg
97 1 yr
85 2 yrs
56 5 yrs
Intraocular pressure (IOP), years (yrs), and millimeters of mercury (mmHg).
Table 5: Summary of GDIs implants surgery in patients with primary congenital glaucoma and secondary glaucoma including: aniridia,
peter’s anomaly, neovascular glaucoma, aphakic glaucoma following congenital cataract extraction, microphthalmia glaucoma after trauma,
glaucoma following retinal detachment surgery, and juvenile glaucoma.
Years Author Type of valveimplanted Eyes Follow-up End point
Success rate
%
1997 Eid
Molteno single or
double plaits,
Soker, Beraveldt
18 47.3 ± 25.1 months 6< IOP <21mmHg 44.4
2007 Autrata Molteno orBearveldt 76 7.1 ± 6.5 yrs 7< IOP <21mmHg
91 at 1 yr
82 at 2 yrs
76 at 3 yrs
71 at 4 yrs
67 at 5 yrs
2008 O’malley Ahmed, Bearveldt,Molteno 79 5.5 yrs (mean) IOP <21mmHg
92–90 at 1 yrs
42–55 after 10 yrs
2009 Al Mobarak Ahmed 42 11.1 ± 5.5 months IOP <22mmHg 73.8 at 1 yr63.3 at 2 yrs
2009 Khan Ahmed 31 11.8 ± 5.6 months IOP <22mmHg 90.9 at 2 yrs58.4 at 2 yrs
Intraocular pressure (IOP), years (yrs), and millimeters of mercury (mmHg).
placement of the implant in the vicinity of the rectus muscle
insertion [57–61].
In Sturge-Weber syndrome higher rate of expulsive
choroidal hemorrhage, choroidal effusion, and prolonged
flat anterior chamber are described. Hamush et al. reported
choroidal detachment in 3 eyes of 11 patients [62]. Amini et
al. reported 3 cases of choroidal detachment in 9 patients with
Sturge-Weber related glaucomawho underwentAhmed valve
implantation [63]. Budenz et al. reported a serous choroidal
detachment in two patients of 9 patients (20%) which
underwent Baerveldt valve implant resolved spontaneously
without the need to drain, the self-limiting nature of this
complacence was due to prophylactic posterior sclerotomies
performed, in more than one quadrant [64].
2.5. Deep Sclerectomy. Deep sclerectomy (NPDS) involves
the unroofing of Schlemm’s canal under a scleral flap, with
concurrent removal of juxtacanalicular trabecular tissues and
creation of a trabeculodescemetic window that provides the
resistance to aqueous drainage, in order to prevent hypotonia.
This procedure is technically more demanding so its use is
not generalized and it is even more limited in childhood.
Only few studies are reported in literature [65, 66]. A
prospective study conducted in Saudi Arabia by Al-Obeidan
et al. regarding NPDS as first surgical choice in 120 patients
with PCG reported a success rate of 82.4% [67].
NPDS is particularly suitable in complicated glau-
coma such as Sturge-Weber syndrome where hypotonia
and choroidal effusion can have catastrophic consequences.
Audren et al. did not report any cases of choroidal effusion of
NPDS in 12 eyes of nine patients (follow-up 26 months) with
glaucoma related to Sturge-Weber syndrome. So it may be
considered theoretically safer than trabeculectomy and GDI
and could be regarded as an alternative when possible [68].
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3. Conclusions
Management of congenital glaucoma is still a challenge
for physicians, starting from diagnosis passing through the
timing and choice of the most appropriate surgical approach
and ending with the long-term follow-up. Today diagnosis
is facilitated with ultrasound biomicroscopy and optical
coherence tomography of the anterior segment which are
imaging techniques which can show the angle and sur-
rounding structures with great detail [69, 70]. Intraocular
pressure generally is measured under anesthesia; however,
most anesthetic drugs lower it. Generally ketamine is avoided
since it raises the values of intraocular pressure. Various
instruments can be used to measure intraocular pressure in
children like the rebound tonometer, the pneumotonometer,
and Perkins applanation tonometer. In particular the I-care
tonometer has shown to be promising in measuring IOP
in awake young children [71]. Its validity and limits are
well known in adult patients [72]. New surgical techniques
and improvements of the traditional ones are available to
manage pediatric glaucoma, which, however, remains still a
challenging and niche type of surgery, probably also due to
its low worldwide incidence. The different clinical situations
should always beweighed against the risks associatedwith the
procedures for the individual patients.
It is generally accepted that angle surgery remains the first
choice in mild cases and both goniotomy and trabeculotomy
have good success rates.
Trabeculectomy with or without MMC is preferred in
refractory cases, in aphakic eyes and in older children. GDIs
have a good success rate in aphakic eyes.
NPDS is still rarely used to date for long-term follow-up
are available but medium term results of on-going studies are
encouraging. There is also a paucity of information on sight-
threatening complications. De Silva et al. evaluate the risk of
glaucomatous progression in 19 patients (mean follow up of
33 years) evaluating at each control: elevation of the disk, IOP,
progression of optic disk cupping, and visual fields.
Goniotomy was the first surgical approach in 27 eyes, 2 of
these eyes needed a second goniotomy. Nine eyes (30%) were
treated with trabeculectomy: 2 eyes with MMC 1 eye with
𝛽-irradiation, 1 eye secondary trabeculectomy with MMC
after 19 years, and 2 eyes requiring transscleral cyclodiode
laser. A total of 9 eyes (30%) showed progressive PCG,
with a reduction of visual acuity >0.2logMAR units and/or
progression of optic disk cupping >0.2 cup/disk ratio as a
consequence of elevated IOP (>21mmHg). The authors have
found that the glaucomatous progression can occur many
years after its stabilization and at any time during the follow-
up period.
The authors hypothesized that the increased visual
impairmentwith long-term follow-up is partly a consequence
of sight threatening PCG progression or ocular-comorbidity
that can occur at any point in the follow-up period [73].
These results underscore the importance of a life-long
assessment and necessity of monitoring the progression of
damage. Standard achromatic perimetry is currently the gold
standard for detecting visual field loss in glaucoma and to
monitoring disease progression over time. Despite advances
in imaging of the optic nerve and the retinal nerve fiber layer
none of the available methods has been proven to be helpful
in the clinical setting for longitudinal assessment of glaucoma
[74, 75].
Considerable progress has been made in the in the diag-
nosis and management of congenital glaucoma but poten-
tially it remains cause of blindness, for this reason innovative
studies are required to improve the existing medical and
surgical options and to experiment newer.
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